‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study

Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.

3d render illustration of human digestive system - front view

Allergan PLC has taken some flak from investors for a recent spate of smaller, earlier-stage deals, but the company’s executives say its “open science” strategy is paying off, most recently via the decision to exercise an option to buy Motus Therapeutics Inc. (formerly Rhythm Health Inc.) after completion of a successful Phase IIb clinical trial for the diabetic gastroparesis drug relamorelin.

Allergan didn’t reveal detailed results from the trial, but the data apparently were significant enough to justify the $200m option...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip